The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index; 4 of the 10 sources its claims cite were checked for support.
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Open accessAbstract
BACKGROUND: Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma. METHODS: CAR-positive (CAR+) T cells. The primary end point was an overall response (partial response or better); a key secondary end point was a complete response or better (comprising complete and stringent complete responses). RESULTS: nucleated cells) was confirmed in 33 patients, representing 26% of all 128 patients who were treated and 79% of the 42 patients who had a complete response or better. The median progression-free survival was 8.8 months (95% confidence interval, 5.6 to 11.6). Common toxic effects among the 128 treated patients included neutropenia in 117 patients (91%), anemia in 89 (70%), and thrombocytopenia in 81 (63%). Cytokine release syndrome was reported in 107 patients (84%), including 7 (5%) who had events of grade 3 or higher. Neurotoxic effects developed in 23 patients (18%) and were of grade 3 in 4 patients (3%); no neurotoxic effects higher than grade 3 occurred. Cellular kinetic analysis confirmed CAR+ T cells in 29 of 49 patients (59%) at 6 months and 4 of 11 patients (36%) at 12 months after infusion. CONCLUSIONS: Ide-cel induced responses in a majority of heavily pretreated patients with refractory and relapsed myeloma; MRD-negative status was achieved in 26% of treated patients. Almost all patients had grade 3 or 4 toxic effects, most commonly hematologic toxic effects and cytokine release syndrome. (Funded by bluebird bio and Celgene, a Bristol-Myers Squibb company; KarMMa ClinicalTrials.gov number, NCT03361748.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 of 10 cited sources checked · 2 supported · 0 flagged · accuracy not yet measured
Every source the paper cites for this claim was checked and supports it.
In the paper
“The B-cell maturation antigen (BCMA)-directed CAR T cell idecabtagene vicleucel (ide-cel, also called bb2121) showed promising efficacy in a phase 1 study involving patients with relapsed or refractory myeloma.11”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > D
What the sources say
- Supportedcites [11] 11. Raje N, Berdeja J, Lin Y, et al. Anti- BCMA CAR T-cell therapy bb2121 in re- lapsed or refractory multiple myeloma. N Engl J Med 2019; 380: 1726-37. source
The Methods identify bb2121 as an anti-BCMA CAR T-cell therapy studied in a phase 1 trial involving patients with relapsed or refractory multiple myeloma. The Discussion reports an 85% clinical response rate, supporting the characterization of its efficacy as promising. (LLM, conf=0.94)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“These efficacy results compare favorably with results in similarly heavily pretreated patients with relapsed or refractory myeloma treated with two recently approved regimens, selinexor plus dexamethasone and belantamab mafodotin (median progression-free survival, 3.7 months and 2.9 months, respectively).5,17”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
What the sources say
- Supportedcites [5] 5. Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 2019; 381: 727-38. source
The Methods and Discussion describe patients with triple-class refractory myeloma who were heavily pretreated, with a median of seven previous regimens. The Efficacy section reports median progression-free survival of 3.7 months with selinexor plus dexamethasone. This citation supports the selinexor result; the separate belantamab result is not attributed to this paper. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [17] 17. Lonial S, Lee HC, Badros A, et al. Belan- tamab mafodotin for relapsed or refracto- ry multiple myeloma (DREAMM-2): a two- arm, randomised, open-label, phase 2 study. Lancet Oncol 2020; 21: 207-21. source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: Cross-trial comparisons of progression-free survival between the KarMMa study and trials of selinexor plus dexamethasone or belantamab mafodotin are valid.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Observed toxic effects were consistent with those in previous reports.11”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
What the sources say
- Partly supportedcites [11] 11. Raje N, Berdeja J, Lin Y, et al. Anti- BCMA CAR T-cell therapy bb2121 in re- lapsed or refractory multiple myeloma. N Engl J Med 2019; 380: 1726-37. sourceExperimental — accuracy not yet measured
The Results (Safety; page unavailable) document the observed toxic effects. The Discussion compares them with previous studies, but reports a lower incidence of severe cytokine release syndrome with bb2121 and cautions that cross-study comparisons are complicated. It does not establish that the toxic effects were generally consistent with previous reports. (LLM, conf=0.82)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Duration of undetectable sBCMA correlated with response duration, and clearance of sBCMA at month 2 was associated with longer progression-free survival (Fig. S5E and S5F).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Figure 2 (facing page). Progression-free Survival, Duration of Response, and Overall Survival.
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Rests on an assumption: Soluble BCMA is a serum-based universal marker of myeloma burden.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“with peak levels higher in patients having cytokine release syndrome of grade 3 or higher (Fig. S6).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“a somewhat higher frequency and somewhat greater depth of response were observed at the 450 × 10 6 dose (response in 81% of the pa-tients and complete response or better in 39%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At baseline, 110 of 112 tumor samples (98%) expressed BCMA, with 109 having at least 50% BCMA-positive plasma cells, and all the patients had detectable levels of sBCMA.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Figure 2 (facing page). Progression-free Survival, Duration of Response, and Overall Survival.
Strength:plain· not yet calibratedn = 112Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A response was observed in 73% of the treated patients, and a complete response or better was observed in 33%;”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Baseline cytokine levels were not associated with higher-grade cytokine release syndrome or neurotoxic effects.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“with an incidence of response to bridging therapy of 4%”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- Probably not a substantial claim. 12
- It may state two separate claims as one. 32
- The quote only partly states this claim. 1
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In contrast, CD19 epitope loss is reported to be a relatively common escape mechanism after treatment with CD19-directed CAR T-cell therapy, especially in patients with acute leukemia.18,19”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
What the sources say
- Partly supportedcites [18] 18. Cheng J, Zhao L, Zhang Y, et al. Un- derstanding the mechanisms of resis- tance to CAR T-cell therapy in malignan- cies. Front Oncol 2019; 9: 1237. sourceExperimental — accuracy not yet measured
The Tumor Factors section reports that loss of the targeted CD19 epitope enabled escape after anti-CD19 CAR T-cell therapy in relapsed B-ALL. It also reports that target-antigen-negative relapse accounts for approximately 9–25% of B-ALL relapses, but does not establish that epitope loss specifically is relatively common or more common in acute leukemia than in other malignancies. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [19] 19. Badar T, Shah NN. Chimeric antigen receptor T cell therapy for acute lympho- blastic leukemia. Curr Treat Options On- col 2020; 21: 16. source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among patients with persistent grade 3 or 4 neutropenia (52 patients) or thrombocytopenia (62 patients) 1 month after infusion, the median time to recovery to grade 2 or lower was 1.9 months (range, 1.2 to 5.6) and 2.1 months (range, 1.2 to 13.8), respectively”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Safety
Strength:plain· not yet calibratedn = 52Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan-Meier estimated median progression-free survival was 8.8 months overall (95% CI, 5.6 to 11.6), 12.1 months (95% CI, 8.8 to 12.3) at the 450 × 10 6 dose, and 20.2 months (95% CI, 12.3 to could not be estimated) in patients having a complete or stringent complete response”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The 128 treated patients had received a median of 6 previous antimyeloma regimens (range, 3 to 16), and 120 (94%) had received previous autologous hematopoietic stem-cell transplants (Table 1).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Patients
Strength:plain· not yet calibratedn = 128Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although high interpatient variability was observed at all doses, upper quartiles of exposure (area under the curve of the transgene level from time of dose to 28 days [AUC 0-28 days ]) were observed more frequently at the 450 × 10 6 dose (Fig. 3B).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Cellular Pharmacokinetic Profile and Immunogenicity
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among treated patients, 5 were positive for antidrug antibodies before infusion.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Cellular Pharmacokinetic Profile and Immunogenicity
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Baseline sBCMA levels were elevated in treated patients and de-creased rapidly after infusion in patients who had a response, with nadir values achieved within 3 months (Fig. 3A and Fig. S5B and S5C).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: Soluble BCMA is a serum-based universal marker of myeloma burden.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Neurotoxic effects developed in 23 patients (18%) and were of grade 3 in 4 patients (3%); no neurotoxic effects higher than grade 3 occurred.”
- Also stated in: § Table 1. (Continued.) · plain
“Investigator-identified neurotoxic effects were reported in 23 patients (18%), of whom 4 (3%) had grade 3 events; no grade 4 or 5 neu-rotoxic effects were observed”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Abstract
Strength:plain· not yet calibratedn = 128Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Table 1. (Continued.) · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median time to first response was 1.0 month (range, 0.5 to 8.8); the median time to a complete response or better was 2.8 months (range, 1.0 to 11.8).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At doses of 150 × 10 6 , 300 × 10 6 , and 450 × 10 6 CAR+ T cells, neurotoxic effects of any grade were reported in 0 of 4 patients, 12 of 70 patients (17%), and 11 of 54 patients (20%), respectively, with grade 3 events in 0 patients, 1 patient (1%), and 3 patients (6%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Table 1. (Continued.)
Strength:plain· not yet calibratedn = 54Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Antidrug antibodies had no effect on the incidence of response or of complete response or better and had no noticeable effect on progression-free survival.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Cellular Pharmacokinetic Profile and Immunogenicity
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The absence of a detectable effect of antidrug antibodies on efficacy is not due to insufficient statistical power.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan-Meier estimated median overall survival was 19.4 months (95% CI, 18.2 to could not be estimated), with an overall survival of 78% at 12 months (Fig. 2D).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Exposures were higher in patients who had a response than in those who did not (Fig. S5A), and higher exposure was associated with deeper response and longer progression-free survival (Fig. 3C and 3D).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Cellular Pharmacokinetic Profile and Immunogenicity
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Achievement of undetectable sBCMA levels increased with depth of response (17 of 27 pa-”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe quote only partly states this claim.
- Rests on an assumption: Soluble BCMA is a serum-based universal marker of myeloma burden.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At doses of 150 × 10 6 , 300 × 10 6 , and 450 × 10 6 CAR+ T cells, cytokine release syndrome of any grade was observed in 2 of 4 patients (50%), 53 of 70 patients (76%), and 52 of 54 patients (96%), respectively, with cytokine release syndrome of grade 3 or higher observed in 0 patients, 4 patients (6%), and 3 patients (6%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Table 1. (Continued.)
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan-Meier estimate for median duration of response was 10.7 months (95% CI, 9.0 to 11.3) overall and 11.3 months (95% CI, 10.3 to 11.4) at the 450 × 10 6 dose”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cytokine release syndrome was reported in 107 patients (84%), including 7 (5%) who had events of grade 3 or higher.”
- Also stated in: § Table 1. (Continued.) · plain
“Cytokine release syndrome occurred in 107 patients (84%) and was mostly of grade 1 or 2 (Table 2 and Table S10).Five patients (4%) had grade 3 cytokine release syndrome, 1 (<1%) had grade 4, and 1 (<1%) had grade 5 (300 × 10 6 dose level).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Abstract
Strength:plain· not yet calibratedn = 128Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Table 1. (Continued.) · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Infections occurred in 88 patients (69%) and were of grade 3 or 4 in 28 (22%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Safety
Strength:plain· not yet calibratedn = 88Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“including many with a high tumor burden, high-risk cytogenetic abnormalities, and extramedullary disease.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Common toxic effects among the 128 treated patients included neutropenia in 117 patients (91%), anemia in 89 (70%), and thrombocytopenia in 81 (63%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Abstract
Strength:plain· not yet calibratedn = 128Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After disease progression, 28 patients were retreated with ide-cel (Table S4).Six patients (21%) had a second response, with durations of response ranging from 1.9 to 6.8 months; all the patients who had a response were retreated at a dose higher than their initial dose.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Most grade 3 or 4 events were hematologic toxic effects, including neutropenia in 114 patients (89%), anemia in 77 (60%), and thrombocytopenia in 67 (52%), and were at least partially related to the lymphodepleting chemotherapy administered before ide-cel infusion.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Safety
Strength:plain· not yet calibratedn = 114Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 44 treated patients (34%) died during the study, with most deaths (27) attributed by the investigator to complications of myeloma progression (Table S12).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Table 1. (Continued.)
Strength:plain· not yet calibratedn = 44Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Levels of proinflammatory markers, including cytokines, ferritin, and C-reactive protein, increased early after ide-cel infusion and decreased by month 1”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The response duration increased with the depth of response; the median response duration was 4.5 months (95% CI, 2.9 to 6.7), 10.4 months (95% CI, 5.1 to 11.3), and 19.0 months (95% CI, 11.3 to could not be estimated) in patients having a best response of partial response (27 patients), very good partial response (25 patients), and complete or stringent complete response (42 patients),”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At the target doses of 150 × 10 6 , 300 × 10 6 , and 450 × 10 6 CAR+ T cells, a response was observed in 2 of 4 patients (50%), in 48 of 70 patients (69%), and in 44 of 54 patients (81%), respectively, and a complete response or better was observed in 1 of 4 patients (25%), in 20 of 70 patients (29%), and in 21 of 54 patients (39%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Five patients (4%) died after 6 months from unrelated adverse events, and an additional 8 patients (6%) died after disease progression.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Table 1. (Continued.)
Strength:plain· not yet calibratedn = 5Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Minimal residual disease (MRD)-negative status (<10 -5 nucleated cells) was confirmed in 33 patients, representing 26% of all 128 patients who were treated and 79% of the 42 patients who had a complete response or better.”
- Also stated in: § Efficacy · plain
“Of the 42 patients with a complete or stringent complete response, 33 (79%) also had MRDnegative status at a sensitivity level of 10 -5 , corresponding to 26% (95% CI, 19 to 34) of the treated population; the remaining 9 patients (21%) could not be evaluated for MRD”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Abstract
Strength:plain· not yet calibratedn = 33Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Efficacy · plain
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“High-grade hematologic toxic effects were common but transient.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The fact that MRDnegative responses occurred in approximately a quarter of the patients highlights the depth of response induced by ide-cel.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: MRD negativity at a sensitivity of 10^-5 is a valid measure of depth of response and clinical benefit.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study protocol was approved by local or independent institutional review boards or ethics committees at participating sites.All the patients provided written informed consent.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Study Oversight
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Nearly all tumors expressed BCMA, a finding that supports the use of ide-cel in relapsed and refractory myeloma without restriction based on tumor BCMA expression.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: BCMA expression is required for ide-cel efficacy, so lack of tumor BCMA expression would limit its use.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The primary efficacy analysis was performed in the population of patients treated with ide-cel (128 patients).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Statistical Analysis
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Between December 13, 2017, and November 13, 2018, a total of 140 patients were enrolled and underwent leukapheresis, of whom 128 received ide-cel infusions.Twelve patients discontinued the study before ide-cel infusion (including 1 patient who discontinued after unsuccessful manufacture of the CAR T-cell product)”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Patients
Strength:plain· not yet calibratedn = 140Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study was designed by the authors in conjunction with the sponsors and conducted in accordance with the International Council for Harmonisation guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Study Oversight
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The sample size for the primary end point (overall response) was based on a onesample binomial test with normal approximation, under the assumption of 15% dropout between the time of enrollment and ide-cel treatment.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Statistical Analysis
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Statistical tests were not performed on subgroup analyses.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Statistical Analysis
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The primary end point was an overall response (partial response or better), defined according to IMWG Uniform Response Criteria for Multiple Myeloma 12 as assessed by an independent review committee.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > End Points and Assessments
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“MRD negativity was evaluated in bone marrow aspirates by next-generation sequencing (clonoSEQ, Adaptive Biotechnologies) with a minimum cutoff of 10 -5 nucleated cells.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > End Points and Assessments
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The actual doses delivered were within 20% of the target doses.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Study Design and Patients
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03.Cytokine release syndrome was graded according to published criteria (Table S2).14”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > End Points and Assessments
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper relies on this without support.
Soluble BCMA is a serum-based universal marker of myeloma burden.
“Soluble BCMA was assessed as a serum-based universal marker of myeloma burden.”
The paper relies on this without support.
Cross-trial comparisons of progression-free survival between the KarMMa study and trials of selinexor plus dexamethasone or belantamab mafodotin are valid.
“These efficacy results compare favorably with results in similarly heavily pretreated patients with relapsed or refractory myeloma treated with two recently approved regimens, selinexor plus dexamethasone and belantamab mafodotin (median progression-free survival, 3.7 months and 2.9 months, respectively).5,17”
The paper relies on this without support.
MRD negativity at a sensitivity of 10^-5 is a valid measure of depth of response and clinical benefit.
“The fact that MRDnegative responses occurred in approximately a quarter of the patients highlights the depth of response induced by ide-cel.”
The paper relies on this without support.
BCMA expression is required for ide-cel efficacy, so lack of tumor BCMA expression would limit its use.
“Nearly all tumors expressed BCMA, a finding that supports the use of ide-cel in relapsed and refractory myeloma without restriction based on tumor BCMA expression.”
The paper relies on this without support.
The absence of a detectable effect of antidrug antibodies on efficacy is not due to insufficient statistical power.
“Antidrug antibodies had no effect on the incidence of response or of complete response or better and had no noticeable effect on progression-free survival.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are newly approved CAR-T products targeting BCMA that are active in relapsed refractory myeloma.89,90”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [89]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Safety of ide-cel remained consistent with the IA, with no parkinsonism, Guillain-Barré syndrome, or SPMs of T-cell origin reported. 13”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Common side effects such as CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) were mostly low grade, indicating manageable toxicity.”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [243]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The median duration of response (mDOR) was 11 months in patients achieving CR and 19 months in those achieving stringent complete response (sCR).”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [243]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of BCMA-directed therapies, including belantamab mafodotin, idecabtagene vicleucel (ide-cel), ciltacabtagene autoleucel (cilta-cel) and teclistamab, have shown efficacy in clinical trials and are approved for the treatment of relapsed or refractory multiple myeloma4–9.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Median DOR and PFS were 10.7 months and 8.8 months, respectively, for ide-cel, and were both not reached for cilta-cel5,6.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although follow-up is still ongoing, among patients with ≥CR, DOR and PFS at 15 months with elranatamab were comparable to those observed with other BCMA-targeted T-cell-redirecting therapies, suggesting similar outcomes once a deep response is achieved5,24,25.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High response rates have been reported with the BCMA chimeric antigen receptor (CAR) T-cell therapies, ide-cel and cilta-cel, with responses reported in 73% and 97% of treated patients, respectively.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In comparison to other BCMA-targeted T-cell-redirecting therapies, the rate of hematologic AEs with elranatamab was similar or lower after a similar follow-up4–6.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CAR-T therapy requires that patients have access to specialized care centers and can wait the minimum 4-week period for production, which can result in attrition rates of approximately 10 to 15%,6-8”
From Teclistamab in Relapsed or Refractory Multiple Myeloma (2022) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among 128 patients with relapsed refractory myeloma treated on a phase II trial, ide-cel was associated with a response rate of 73%.89 Thirty three percent of patients had a complete response or better. The median PFS was 8.8 months.”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“Cytokine release syndrome was seen in 84%, and 5% were grade 3 or higher. Neurotoxicity was seen in 18%, and was grade 3 in 3%.”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“Chimeric antigen receptor (CAR) T-cell therapy has shown promising ef fi cacy in patients with TCE R/RMM. 13-21”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“In the KarMMa study involving 128 patients with RRMM, the overall response rate (ORR) to a single infusion of Abecma was 73%, with a complete response (CR) rate of 33%.”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [243]
The cited source says what the claim attributes to it.
In the citing paper
“Abecma has demonstrated the ability to induce rapid, deep, and long-lasting remissions with just one infusion, providing a new and effective personalized therapy option for MM patients [227, 243, 258, 259].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [243]
The cited source says what the claim attributes to it.
In the citing paper
“In contrast, higher-grade cytokine release syndrome and neurotoxic events have been described after CAR-T administration in patients with multiple myeloma.6,8”
From Teclistamab in Relapsed or Refractory Multiple Myeloma (2022) · cites this paper as [6]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Similarly, patients with advanced disease stage (R-ISS stage III) have consistently shown poorer outcomes irrespective of the therapy received4–6,19–22.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“Recently approved therapies such as selinexor, 9 belantamab mafodotin, 10 idecabtagene vicleucel, 11 and ciltacabtagene autoleucel 12 have had clinical benefit in patients with relapsed or refractory multiple myeloma.”
From Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma (2022) · cites this paper as [11]
Citations
Cites
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationCurrent concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.
Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817226 · Cited by 1,730
Self-citationLonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Self-citationOral selinexor-dexamethasone for triple-class refractory multiple myeloma.
Chari, A., Vogl, D. T., Gavriatopoulou, M., Nooka, A. K., Yee, A. J., Huff, C. A., Moreau, P., Dingli, D., Cole, C., Lonial, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903455 · Cited by 666
Self-citationOutcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., Gupta, R., Varnado, W., Fiala, M. A., Chhabra, S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0435-7 · Cited by 616
Friedman, K. M., Garrett, T. E., Evans, J. W., Horton, H. M., Latimer, H. J., Seidel, S. L., Horvath, C. J., & Morgan, R. A. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.001 · Cited by 205
Treatment of relapsed and refractory multiple myeloma
Sonneveld, P., & Broijl, A. (2016) · Haematologica · doi:10.3324/haematol.2015.129189 · Cited by 181
CAR T-cell therapy in hematologic malignancies: a voyage in progress.
Holstein, S. A., & Lunning, M. A. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1674 · Cited by 172
Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies.
Cheng, J., Zhao, L., Zhang, Y., Qin, Y., Guan, Y., Zhang, T., Liu, C., & Zhou, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01237 · Cited by 153
Flagged first, then by citations
Cited by
Sorted by citations
Items 2,301–2,400 of 2,535
Kelly, C. W., Bahr, R., Zhu, W., Keyvanfar, K., Dagur, P., & Cordes, S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.01.700582
Camviel, N., Gambarotto, D., André, V., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.004
“1,2 While fast and deep responses can be achieved, disease relapse is often driven by mechanisms that include chronic antigen stimulation and CAR-T cell exhaustion, BCMA downmodulation, or genetic loss.”
Kang, Y., Liu, Q., Liu, Q., Xie, W., Sun, C., & Mei, H. (2026) · Blood Cancer Journal · doi:10.21203/rs.3.rs-8750940/v1
The cellular orchestra of CAR T success
Samur, M., & Munshi, N. C. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.01.017
Self-citationKhatib, H. A., Parizat, A., Halloun, J., et al. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70139
Lal, B. M., & Kumar, S. K. (2026) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-026-00771-8 · Cited by 3
“…therapy can now have lasting remissions with newer therapies like chimeric antigen receptor (CAR) T-cell therapy, bispecific T-cell engagers (BiTEs), and antibody-drug conjugates Shaji K. Kumar kumar.shaji@mayo.edu (ADCs), with no detectable malignant plasma cells using standard techniques [3–7].”
Mieloma múltiple: del genoma a la medicina de precisión
Polo, V. A., Omaña, P., Daza-Buitrago, J. A., & Calcetero, C. F. G. (2026) · Revista Colombiana de Hematología y Oncología · doi:10.51643/22562915.847
Song, Z., Fu, Q.-C., & Du, J. (2026) · Hematological Oncology · doi:10.1002/hon.70179 · Cited by 1
“The incidence of severe CRS ( ≥ grade 3) was reported to be lower than 10% in all these four CAR T products [17, 23, 29, 33].”
InfluentialPérez-Prol, C., Aquerreta, D., Rodríguez-Otero, P., et al. (2026) · Neurología · doi:10.1016/j.nrl.2026.502012
Yasui, H., Doki, N., Yan, W., Imai, K., & Ishida, T. (2026) · Cells · doi:10.3390/cells15040380 · Cited by 2
Bayly-McCredie, E., Prince, H. M., Yannakou, C. K., Fiorenza, S., & Wisniowski, B. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2634055
“While cross-trial comparisons are limited by trial design, elranatamab and the other BsAbs are clearly less efficacious than autologous BCMA-targeting CAR T cell therapies including ciltacabtagene autoleucel (97% ORR) and idecabtagene vicleucel (73% ORR) [102,103].”
Hämatologische Neoplasien und solide Tumore
Ganser, A., Hertenstein, B., & Ludwig, W. (2026) · Springer eBooks · doi:10.1007/978-3-662-72738-6_5
Cheng, Y., & Li, Y. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.01.708830
Cardús, O., Mañé-Pujol, J., de Daniel, A., Moreno, D. F., Gremen, T., Battram, A. M., Vaqué-Salsench, S., Pérez-Amill, L., Llobregat, H., Mármol, J. C., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011864
Cheng, Y., & Li, Y. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.01.708827
Overcoming Microenvironment-Driven Resistance to CAR-T Therapy in Multiple Myeloma
Saez, G., Khusial, R., Hamedi, K. R., Arreola, N., Khuu, H., & Kissel, H. (2026) · Lymphatics · doi:10.3390/lymphatics4010015 · Cited by 1
“Hematologic adverse events occurred in over 90% of the patients, with most recovering within 1–2 months (Table 1) [6–9].”
2. Update on multiple myeloma -including related diseases-
Ishida, T. (2025) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.114.473
Adenosine Pathway of T Cell Regulation with a Chimeric Antigen Receptor
Mironova, K. A., Zotova, A. D., & Deyev, I. E. (2026) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162026600376
CAR-T cell therapy as a promising treatment for systemic lupus erythematosus (literature review)
Сергеевна, Л. Е., Н., М. А., & Lutskovich, D. V. (2025) · Vestnik of Vitebsk State Medical University · doi:10.22263/2312-4156.2025.5.17
Review of advances in CAR-T therapies in malignant hematology
Amirmokhtari, N., & Lutfi, F. U. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1768614
Varga, C., Robinson, M. M., Davis, J. A., et al. (2026) · Blood Cancer Journal · doi:10.1038/s41408-026-01469-z
Self-citationShah, R., Vojjala, N., Cheng, T., et al. (2026) · Annals of Hematology · doi:10.1007/s00277-026-06927-z
Ling, J., Wang, W. J., & Wang, S. A. (2026) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.70026 · Cited by 1
Iriuchishima, H., Saito, A., Mihara, M., Kanaya, S., Yoshizawa, R., Isoda, A., & Matsumoto, M. (2026) · Cancers · doi:10.3390/cancers18071048
“T therapy [29], and bispecific antibody drugs [30–32].”
Oner, A., Nooteboom, N., Oosting, L. T., Kosterink, J. G. W., Dekkers, B. G. J., van der Graaf, A. C., van Meerten, T., Krenning, G., Swart, D. H., Dennebos, R., et al. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040414
Repurposing Hetrombopag for Multiple Myeloma by Targeting PNPO: A Celastrol‐Inspired Approach
Yu, T., Wang, C., Xie, J., Wei, Y., Cui, H., Zhang, H., Zhou, F., Deng, Z., Yang, Y., & Gu, C. (2026) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.70227
Engineering TCR-directed T-cells for the treatment of multiple myeloma
Mubin, N., Ignatz-Hoover, J. J., & Driscoll, J. J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1755096 · Cited by 1
CAR T cells for pediatric CNS tumors: Clinical experience and reverse translational opportunities
Song, K.-W., Kaur, A. P., & Ramakrishna, S. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201196
“Hence, multiple CAR T cell products are now FDA-approved, including CD19 CAR T cells for refractory adult leukemia/lymphomas, 6–10 BCMA CAR T cells for multiple myeloma, 11,12 and one CD19 CAR T cell product (tisagenlecleucel) for pediatric leukemia patients.”
A novel small-molecule inhibitor of IRF4 selectively suppresses multiple myeloma
Zhang, L., Ding, X., Wu, M., Zhang, J.-Z., Chen, H., Liu, M., Qiu, W.-W., & Yi, Z. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102176
Modi, K., Mahadevia, H. J., Shah, R., et al. (2026) · Cardio-Oncology · doi:10.1186/s40959-026-00471-5
“Initially dominated by lymphoma and leukemia, the proportion of MM increased from 8.9% in 2020 to 23.4% in 2022, reflecting the integration of ide-cel and cilta-cel into practice following the KarMMa and CARTITUDE-1 trials [8, 9].”
InfluentialMarcos-Kovandzic, L. (2024) · theses.fr (ABES) · doi:10.70675/3bde4b45z23ecz4b69zb90dzabccd7cd7fca
Dissecting the role of long non-coding RNA in multiple myeloma
Zocchi, S. (2024) · theses.fr (ABES) · doi:10.70675/22f35f26z6442z47d6z8cdaz153527b5df6e
Developing logic-gated CAR T cells for saferT-cell lymphoma therapy
Bourbon, E. (2025) · theses.fr (ABES) · doi:10.70675/11e2363dzeb1fz46bcza38dz6f6c7aa5545d
Boretti, A. A. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00103
Bispecific Antibodies and CAR-T cell Therapy in Multiple Myeloma
Locke, M., Lee, A., & Nieto, M. J. (2026) · Journal of Clinical Haematology · doi:10.33696/haematology.7.074
Role B-cell maturation antigenu v léčbě mnohočetného myelomu
Vilímová, K., Kušnierová, P., Mihályová, J., & Hájek, R. (2026) · Klinická biochemie a metabolismus · doi:10.61568/kbm.2026.001
Zhao, N., Li, W., Chen, Q., et al. (2026) · Hematology · doi:10.1080/16078454.2026.2662692
He, L., Sun, Y., Ma, B., Lang, G., Wen, J., Blumenschein, G. B., & Ma, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1772428
Targets and Therapies in Hematologic Malignancies
Bendale, A. R., Basuri, T. S., Mohapatra, R., Nayak, R. R., & Mohapatra, T. K. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814113126010009
Gustine, J. N., Attar, N., Puliafito, B. R., Cirstea, D. D., Branagan, A., Yee, A. J., & Raje, N. (2026) · Blood Cancer Journal · doi:10.1038/s41408-026-01510-1
Self-citationCAR T-Cell Therapy and Complications
McEvoy, C. A., Arnold, E., & Gutiérrez, C. (2026) · Springer eBooks · doi:10.1007/978-3-319-74698-2_206-1
Development of a Fully Non-Viral 1XX-enhanced BCMA CAR-T Cell Therapy for Multiple MyelomaPreprint
Talbot, A., Li, K., Lee, J. H. J., Lang, S., Liu, C., Kalter, N., Li, Z., Mortazavi, Y., Almudhfar, N., Muldoon, J. J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.20.719660
Elessawey, H. M., Safwat, G., Mohamed, R. H., et al. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11822-x
Du, L., Jiang, Y., Zhou, Q., & Xu, F. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1830089
Xu, X., Dong, C., Guo, J., Chang, X., Zhang, Y., Gou, S., Xue, L., & Li, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1744250
Targeting the immunological synapse in multiple myeloma
Sumei, L., & Bahmani, F. (2026) · Discover Oncology · doi:10.1007/s12672-026-05125-7
“…observations highlight that relapse (both antigen-positive and anti-gen-negative), inter-patient variability in durability, and sanctuary-site biology are recurring, clinically meaningful synaptic failure modes that must be acknowledged explicitly when claiming therapeutic promise [93, 119, 120].”
InfluentialKo, K., Zhmakin, V., Wang, D., & Chen, M.-K. (2026) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000006496
Moon, S., Kang, D.-W., Choi, Y. J., & Shin, S. (2026) · Pharmaceuticals · doi:10.3390/ph19050669 · Cited by 2
“In this context, minimal residual disease (MRD) negativity has been established as a key surrogate endpoint for long-term survival, emphasizing the need for more potent and targeted therapeutic approaches [10,11].”
Dennebos, R., Corrales, M. G., Lysandrou, M., Smit, N. A. M., Qi, Y., van Meerten, T., Kosterink, J. G. W., Huls, G. A., Lourens, H.-J., Gareb, B., et al. (2026) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2026.100559
Olszewska‐Szopa, M., Vesole, D. H., & Jurczyszyn, A. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.04.021
Li, H., Xia, Q., Yu, M., Lv, Y., Xiao, J., Guo, X., Dong, K., Zhou, Y., Zhong, L., Wang, T., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3227-0
“…3 months post-infusion, after which they gradually decrease, with only 20% of patients exhibiting detectable CAR-T cells at 12 months post-infusion (Munshi et al., 2021; Raje et al., 2019), indicating that the loss of myeloma control beyond the initial 3 – 6 months may be related to the transient…”
Oswald, L. B., Li, X.-Y., Gudenkauf, L., Avila, G. D., Scheiber-Camoretti, D., Small, B. J., Gonzalez, B. D., Hoogland, A., Nguyen, O. L., Rodriguez, Y., et al. (2026) · Bone Marrow Transplantation · doi:10.1038/s41409-026-02899-w
Hou, X., Yang, L., Liu, F., Wang, F., Liu, S., Yao, Y., Wang, Z., Qi, C., Zhu, H., & Yang, Z. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6c00244
Pisaturo, M., Grimaldi, P., Palma, M. D., Onorato, L., D'Ambrosio, A., Frigeri, F., & Coppola, N. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116790
El‐Sehrawy, A. A. M. A., Oriquat, G., Saidov, S., Ruzikulov, U., Shakhmurova, G., Jbl, B. J., Singhal, D., & Shefali (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.121066 · Cited by 1
Yang, M., Zhou, W., Wang, X., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9063774/v1
Zeng, Y., He, C., He, Z., Chen, H., Cheng, F., & Zheng, Y. (2026) · Advanced Science · doi:10.1002/advs.75686 · Cited by 2
Kuipers, M. T., Migchelbrink, J., Kramer, A., Kouwenhoven, M., Zweegman, S., Groen, K., & van de Donk, N. V. (2026) · BioDrugs · doi:10.1007/s40259-026-00784-y
Buczek, T., & Butrym, A. K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1842236
“For these reasons, CAAR-T is currently less compelling in active multiple myeloma than established targets such as BCMA, GPRC5D, or FcRH5 (12, 13, 38).”
InfluentialMartı́nez, D., Sopeña, C., Moreno, M. J., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.05.002
Disparity in access to multiple myeloma CAR-T: a geospatial analysis of distance to CAR-T centers
Daunov, M., Gorham, R., Lytvynova, O., et al. (2026) · Blood Immunology & Cellular Therapy · doi:10.1016/j.bict.2026.100064
Chimeric Antigen Receptor (CAR) T-cell Immunotherapy and Flow Cytometric Monitoring of CAR T Cells
Ling, J., & Wang, S. A. (2026) · Cambridge University Press eBooks · doi:10.1017/9781009397797.042
Cellular Therapies in Solid Tumors: Are We Ready for Primetime?
Maiocco, G., Ernani, V., Gustafson, M. P., Punekar, S. R., Leventakos, K., Molina, J. R., Zakharia, Y., Borad, M. J., & Hazim, A. Z. (2026) · JCO Oncology Practice · doi:10.1200/op-26-00119 · Cited by 1
Research Fronts 2025: Mapping the evolving landscape of global science and technology
Wang, H., Zhou, Q., Fan, W., Yuan, J., Xing, Y., Li, J., Ji, Y., Li, Y., Bian, W., Zhang, C., et al. (2026) · The Innovation · doi:10.1016/j.xinn.2026.101427
Self-citationLiu, X., Hu, H., Dai, Y., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201763
“Chimeric antigen receptor (CAR) T cell therapies have recently emerged as a novel approach for treating cancers 1,2 and immune-related disorders.”
Wu, J., Zheng, R., Ming, X., et al. (2026) · Cell Transplantation · doi:10.1177/09636897261449972
“T cell therapy has demonstrated satisfactory efficacy and controllable toxicities in heavily pretreated R/R MM patients 11,12 .”
InfluentialToho, M., Tabata, R., Shima, K., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70555
Δ-β2M as a dynamic biomarker for predicting ICU admission after CAR T-cell therapy
ANGLEITNER, A. C., Maulhardt, M., Thomson, K., et al. (2026) · Annals of Hematology · doi:10.1007/s00277-026-07075-0
Daneshvar, A., Mashayekhi, R., & Sharifnia, M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.24.727464
Cheng, Y., & Li, Y. (2026) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2026.104346
Soluble-Antigen-Based PET/MR for the Specific Detection of BCMA CAR+ T-Cell Lymphoma.
Zhou, W., Meng, Y., Yan, Y., Tang, L.-J., Yan, J.-J., Pan, D., Chen, C.-Y., Xu, Y.-P., Wang, L.-Z., Wang, X.-Y., et al. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6c00097
Liu, S. X., Wu, J., Liu, J., Wu, K., Huang, Y. Q., Geng, S., Wang, Y., Weng, J., Du, X., & Lai, P. (2026) · ImmunoTargets and Therapy · doi:10.2147/itt.s605729
Clinical implications of minimal residual disease monitoring in multiple myeloma
Yoroidaka, T. (2026) · International journal of hematology · doi:10.1007/s12185-026-04229-8
“Among the 33 patients who achieved CR/sCR and were evaluable for MRD, all were MRD-negative [58].”
High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy
Morgan, G. J., Lee, D. D., Joseph, N. S., Lonial, S., Rodríguez‐Otero, P., & San-Miguel, J. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-517494
Self-citationLi, J., Dowling, M. R., Wronski, M., et al. (2026) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2026.05.027
Understanding Physician Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
Blue, B., Lake, P. W., Pidala, J., Jim, H., Locke, F. L., & Vadaparampil, S. T. (2026) · Journal of Cancer Education · doi:10.1007/s13187-026-02894-1
Antibody–drug conjugates in hematologic malignancies
Patel, K., Strickland, S. A., & Lee, H. C. (2026) · Cancer · doi:10.1002/cncr.70421
CAR T cells for systemic autoimmune diseases.
Rosetti, F., Madera-Salcedo, I., Cenobio, L. A., Aguilar-Fuentes, R., & Crispín, J. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104111
Kikuchi, T., Kondo, U., Sugita, S., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70602
Chen, Q., Sedloev, D., Yao, H., Mao, L.-H., Depke, D., Wang, L., Scheller, M., He, B.-L., Liu, Y., Unglaub, J., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.05.027
“4,32 Owing to their robust proliferative capacity and cytokine release profile, CD4 + CART cells may effectively stimulate myeloid cells to produce inflammatory mediators.”
Jimenez-Mira, C., Tovar, N., Martínez‐Cibrián, N., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70586
“Overall, mPFS and mOS were 10.5 and 15.9 months, respectively; remaining worse than results in pivotal trials 11–13 ; however, our results are in accordance with RWD in PCL/ CNS-MM: a better outcome in patients with CNS-MM was shown in addition to an excellent safety profile 29 and a better outcome…”
InfluentialIbarra-Garcia, V., Calleja-Cervantes, M. E., Rochira, F., Azagra-Barber, I., Martín‐Úriz, P. S., Aguirre-Ruiz, P., Rodríguez-Diaz, S., Martínez-Turrillas, R., Iglesias, E., Ibáñez-Sala, I., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.02.729637
Self-citationLoukhnati, M., Hébraud, B., Cazaux, M., et al. (2026) · Case Reports in Hematology · doi:10.1155/crh/1558475
“Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the management of multiple myeloma (MM) and other hematological malignancies [1, 2].”
Golec, S., Fu, W.-J., Moshier, E., Peleg, A., Pileggi, B., Rossi, A. C., & Sahni, G. (2026) · European Heart Journal Open · doi:10.1093/ehjopen/oeag097
“8,9 The indications continue to expand, now including those with lenalidomide-refractory disease and specifically triple-class exposed relapsed and refractory myeloma.”
Shi, H., Yin, W., Zhang, H., Jiang, X., He, J., Zhu, G., Overstreet, M. G., Cobbold, M., & Shen, L. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.05.730120
CRISPR application in hematological disorders: from bench to bedside
Ladisa, F., Morelli, E., Soncini, D., Garibotto, M., Munshi, N. C., Fulciniti, M., & Cea, M. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025017417
Self-citationBertuglia, G., Nicola, A. D., Gay, F., Larocca, A., Bruno, B., & D’Agostino, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1822419
“CAR-T cell therapies such as idecabtagene vicleucel (ide-cel) (34) and ciltacabtagene autoleucel (cilta-cel) (33), as well as bsAbs including teclistamab (36), elranatamab (35) and linvoseltamab (39) are FDA approved BCMA-targeting therapies that can be used in RRMM.”
Patel, K. K., Hasegawa, K., Ting, J., Sidana, S., Zoratti, M. J., Wennersbusch, D., Kanters, S., Kostic, A., Itani, T., & Hansen, D. K. (2026) · Expert Review of Hematology · doi:10.1080/17474086.2026.2688385
Li, P., Xue, X., & Zhang, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1861111
“Abecma (19) and Carvykti (20) are approved for the treatment of relapsed/refractory multiple myeloma (R/R MM) (Table 1).”
Preleukapheresis risk factors for BCMA CAR-T product manufacturing failure
Sparrow, S., Wolcott, A., Mott, S., et al. (2026) · Blood Immunology & Cellular Therapy · doi:10.1016/j.bict.2026.100068
Angleitner, A. C., Maulhardt, M., Wulf, G. G., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1842487
Camargo, C., Corona-Arias, C. A., Sandoval, Y. C. C., Ballesteros, W. G. G., Agudelo, D. S. J., & Romero, G. I. T. (2026) · Journal of Applied Hematology · doi:10.4103/joah.joah_23_26
Xia, F., Lv, B., Li, X., Tian, M., Gu, X., Zhou, D., Sun, Q., Xia, J., Qi, Y., Zhang, H., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-04988-5
“In studies of B-cell mature antigen (BCMA) CAR-T cell therapy, up to 95% of patients experienced prolonged cytopenia (low blood cell counts), which persisted for at least 30 days in more than half of these patients [7, 8].”
Lopez-Viñas, L., Sánchez, V. F., Cabezudo‐García, P., et al. (2026) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2026.579003
Improved survival in patients admitted to ICU with multiple myeloma: a retrospective cohort analysis
Nakaa, S., Caillot, L., Chermak, A., Kemp, H., Harel, S., Darmon, M., Azoulay, É., & Lemiale, V. (2026) · Annals of Intensive Care · doi:10.1016/j.aicoj.2026.100100
LaGalbo, S., Foley, M. T., Metropulos, A. E., Burton, K. A., & Principe, D. R. (2026) · Current Oncology Reports · doi:10.1007/s11912-026-01791-6
Adrados, A., Pérez‐Fernández, J., García-Vicente, R., Garrote-de-Barros, A., Martínez‐López, J., Linares, M., & Hernández‐Sánchez, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1805129
“Pivotal clinical trials reported complete remission (CR) rates of 33 – 67%, with 87 – 95% experiencing cytokine release syndrome and 18 – 21% neurotoxicity (27, 28).”
Metadata
- Authors
- Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., Moreau, P., Yakoub-Agha, I., Delforge, M., Cavo, M., Einsele, H., Goldschmidt, H., Weisel, K., Rambaldi, A., Reece, D., Petrocca, F., Massaro, M., Connarn, J. N., Kaiser, S., Patel, P., Huang, L., Campbell, T. B., Hege, K., & San-Miguel, J.
- Affiliations
- Harvard University (US)
- Mayo Clinic (US)
- Hackensack University Medical Center (US)
- From the Jerome Lipper Multiple Myeloma Center, Dana–Farber Cancer Institute (N.C.M.), the Veterans Affairs Boston Healthcare System, Harvard Medical School (N.C.M.), and Massachusetts General Hospital (N.R.), Boston, and bluebird bio, Cambridge (F.P., M.M.) — all in Massachusetts; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.); the University of California, San Francisco, San Francisco (N.S.); Icahn School of Medicine at Mount Sinai, New York ...
- ORCID
- Munshi, Nikhil C.
- Anderson, Larry D.
- Shah, Nina
- Madduri, Deepu
- Berdeja, Jesús
- Lonial, Sagar
- Raje, Noopur
- Lin, Yi
- Siegel, David
- Oriol, Albert
- Moreau, Philippe
- Yakoub-Agha, Ibrahim
- Delforge, Michel
- Einsele, Hermann
- Goldschmidt, Hartmut
- Weisel, Katja
- Rambaldi, Alessandro
- Reece, Donna
- Petrocca, Fabio
- Connarn, Jamie N.
- Kaiser, Shari
- Patel, Payal
- Huang, Liping
- Campbell, Timothy B.
- Hege, Kristen
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-25
- Volume
- 384
- Issue
- 8
- Pages
- 705-716
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3133229959
- Semantic Scholar
- fd96e2f87dff7d1153a17b78b56fbbab69cb714e
- Cited by
- 2,560
- References
- 17
- Citations by year
- 2026: 411 · 2025: 486 · 2024: 540 · 2023: 493 · 2022: 436 · 2021: 186
- FWCI
- 150.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- idecabtagene vicleucel, CAR T-cell therapy, relapsed/refractory multiple myeloma, BCMA, minimal residual disease, cytokine release syndrome, neurotoxicity, CAR T cell persistence, progression-free survival, complete response, neutropenia, anemia, thrombocytopenia, chimeric antigen receptor T cells
- MeSH terms
- Receptors, Chimeric Antigen, Progression-Free Survival, Cytokine Release Syndrome, Adult, Aged, Female, Hematologic Diseases, Humans, Male, Middle Aged, Multiple Myeloma, Recurrence, Biomarkers, Immunotherapy, Adoptive, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
